Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Although Novo Nordisk recently announced a price cut for Wegovy (in response to competition from Eli Lillys Zepbound), costs remain highwith significant impacts on both self-funded employers and individuals interested in the benefits of GLP-1s
Tirzepatide induces substantial weight losstypically 5-10% in type 2 diabetes and 15-20% in obesity without diabetes at therapeutic doseswhich can directly reduce cardiac workload and peripheral vascular resistance
Their study, published in Ophthalmology Science , found no association between use of the drug and worsening diabetic retinopathy
Liu Qiang, Chairman of YaoPharma, said: "By leveraging Pfizer's exceptional global development experience and commercialisation network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialisation of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively." Pfizers moves with Metsera and now YaoPharma add to continued competition in the obesity drug market, which has also seen Teva Pharmaceuticals gain US Food and Drug Administration (FDA) approval in August of a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).
Pre-screening is required before purchase
US$ 23.22
US$ 23.33
US$ 21.69
US$ 29.82
